Novo Nordisk announces a $4.1 billion plant in Clayton, North Carolina

Novo Nordisk said on June 24, 2024, that it will invest $4.1 billion (about 27 billion Danish kroner) to build a second fill-and-finish manufacturing facility in Clayton, North Carolina, expanding its ability to produce injectable treatments for obesity and other chronic diseases ^[1]. Fierce Pharma reported that the plant will make semaglutide products Ozempic, for type 2 diabetes, and Wegovy, for obesity ^[2].

The project adds 1.4 million square feet of production space for aseptic manufacturing and finished production processes — roughly doubling the combined square footage of the company's three existing North Carolina facilities ^[1]. Novo called it one of the largest manufacturing investments in its history ^[1]. Early clearing and foundation work is already underway on the 56-acre footprint, and construction will be finalized in stages between 2027 and 2029 ^[1].

The numbers behind the announcement

The facility is expected to add 1,000 jobs on top of the nearly 2,500 Novo Nordisk employees already working in the region, with about 2,000 outside contractors engaged at the peak of construction ^[1]. Butch Lawter, chair of the Johnston County Board of Commissioners, said at the press conference that the county would provide grants to support the expansion, and noted that Novo's 2016 announcement had been "the single largest life sciences investment on state record at the time" — a record he said the company was breaking again ^[1].

The Clayton spending is part of a larger ramp-up. Novo Nordisk said it plans to invest approximately $6.8 billion (45 billion Danish kroner) in production during 2024, up from $3.9 billion (26 billion kroner) in actual investments the prior year, excluding acquisitions ^[1].

The announcement lands in the middle of a capacity race. A month earlier, Eli Lilly disclosed a $5.3 billion investment to increase its own manufacturing capacity ^[2]. Novo's parent, Novo Holdings, is also pursuing a $16.5 billion buyout of contract manufacturer Catalent, under which Novo Nordisk would gain three fill-finish sites for $11 billion ^[2].

Novo has operated in Clayton since 1993 ^[2]. Its first plant there grew through several expansions to 457,000 square feet, and a second plant came online in 2021 at a cost of $2 billion — the company's first site outside Denmark to produce active pharmaceutical ingredients ^[2]. In 2022, Novo opened a 180,000-square-foot plant in Durham, about 40 miles away, where it manufactures oral semaglutide, sold as Rybelsus ^[2]. In March 2023, the company bought 104 adjacent acres in Clayton for $6.8 million ^[2].

The new building is designed with rooftop solar panels and what the company calls innovative water strategies, with a goal of LEED Gold certification ^[1].

Why it matters for patients

"Fill-finish" is the final step in making an injectable drug: putting the medicine into pens or vials under sterile conditions. It has been a well-known chokepoint for GLP-1 supply, and this announcement is aimed squarely at that step ^[1][2].

The practical catch is timing. Construction will not be complete until sometime between 2027 and 2029 ^[1], so this particular investment does not change how many Ozempic or Wegovy pens reach US pharmacies in the near term. The sources do not say when specific doses will become more available, and they do not address current shortage status or pricing — that is not yet known from this material.

CEO Lars Fruergaard Jørgensen framed the expansion in terms of future demand: "It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we're building Novo Nordisk's ability to serve millions more people living with serious chronic diseases in the future" ^[1].

What happens next

• Now: Site clearing and foundation work is underway in Clayton ^[1].
• 2024: Novo plans roughly $6.8 billion in total production investment for the year ^[1].
• 2027–2029: The phased buildup of the new plant is completed ^[1][2].

Novo Nordisk operates strategic production sites in Denmark, the US, France, Brazil and China, with nearly 20,000 people in its manufacturing unit ^[1][2].